President Trump's search for a permanent FDA commissioner remains fluid following Marty Makary's May 2026 resignation, leaving Kyle Diamantas as acting commissioner while White House aides review multiple finalists including policy adviser Heidi Overton, oncologist Jeffrey Vacirca, and Pentagon health official Stephen Ferrara. Trader odds stay dispersed because the process is still in vetting without a confirmed frontrunner, Senate confirmation timeline, or binding deadline before year-end. Key differentiators among mentioned names such as former commissioner Stephen Hahn, Brett Giroir, Grace Graham, and Sara Brenner include prior FDA or HHS leadership, oncology or regulatory expertise, and alignment with current administration priorities on drug approvals, food safety, and industry relations. Support could consolidate behind one candidate through Senate vote counts, direct White House endorsement, or demonstrated ability to navigate confirmation hearings in an election year.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गयाकाइल डायमांटस <1%
स्टीफन हान <1%
ब्रेट गिरोइर <1%
ग्रेस ग्राहम <1%
$39,291 वॉल्यूम
$39,291 वॉल्यूम
30 दिस, 2026
काइल डायमांटस
नहीं
स्टीफन हान
नहीं
ब्रेट गिरोइर
नहीं
ग्रेस ग्राहम
नहीं
सारा ब्रेनर
नहीं
31 दिसंबर तक कोई घोषणा नहीं
नहीं
काइल डायमांटस <1%
स्टीफन हान <1%
ब्रेट गिरोइर <1%
ग्रेस ग्राहम <1%
$39,291 वॉल्यूम
$39,291 वॉल्यूम
30 दिस, 2026
काइल डायमांटस
$10,368 वॉल्यूम
नहीं
स्टीफन हान
$5,255 वॉल्यूम
नहीं
ब्रेट गिरोइर
$5,265 वॉल्यूम
नहीं
ग्रेस ग्राहम
$6,713 वॉल्यूम
नहीं
सारा ब्रेनर
$8,024 वॉल्यूम
नहीं
31 दिसंबर तक कोई घोषणा नहीं
$3,664 वॉल्यूम
नहीं
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.President Trump's search for a permanent FDA commissioner remains fluid following Marty Makary's May 2026 resignation, leaving Kyle Diamantas as acting commissioner while White House aides review multiple finalists including policy adviser Heidi Overton, oncologist Jeffrey Vacirca, and Pentagon health official Stephen Ferrara. Trader odds stay dispersed because the process is still in vetting without a confirmed frontrunner, Senate confirmation timeline, or binding deadline before year-end. Key differentiators among mentioned names such as former commissioner Stephen Hahn, Brett Giroir, Grace Graham, and Sara Brenner include prior FDA or HHS leadership, oncology or regulatory expertise, and alignment with current administration priorities on drug approvals, food safety, and industry relations. Support could consolidate behind one candidate through Senate vote counts, direct White House endorsement, or demonstrated ability to navigate confirmation hearings in an election year.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
बाज़ार खुला: May 12, 2026, 7:59 PM ET
वॉल्यूम
$39,291समाप्ति तिथि
31 दिस, 2026बाज़ार खुला
May 12, 2026, 7:59 PM ETरिज़ॉल्वर
0x69c47De9D...परिणाम प्रस्तावित: नहीं
कोई विवाद नहीं
अंतिम परिणाम: नहीं
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.President Trump's search for a permanent FDA commissioner remains fluid following Marty Makary's May 2026 resignation, leaving Kyle Diamantas as acting commissioner while White House aides review multiple finalists including policy adviser Heidi Overton, oncologist Jeffrey Vacirca, and Pentagon health official Stephen Ferrara. Trader odds stay dispersed because the process is still in vetting without a confirmed frontrunner, Senate confirmation timeline, or binding deadline before year-end. Key differentiators among mentioned names such as former commissioner Stephen Hahn, Brett Giroir, Grace Graham, and Sara Brenner include prior FDA or HHS leadership, oncology or regulatory expertise, and alignment with current administration priorities on drug approvals, food safety, and industry relations. Support could consolidate behind one candidate through Senate vote counts, direct White House endorsement, or demonstrated ability to navigate confirmation hearings in an election year.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
वॉल्यूम
$39,291समाप्ति तिथि
31 दिस, 2026बाज़ार खुला
May 12, 2026, 7:59 PM ETरिज़ॉल्वर
0x69c47De9D...परिणाम प्रस्तावित: नहीं
कोई विवाद नहीं
अंतिम परिणाम: नहीं
President Trump's search for a permanent FDA commissioner remains fluid following Marty Makary's May 2026 resignation, leaving Kyle Diamantas as acting commissioner while White House aides review multiple finalists including policy adviser Heidi Overton, oncologist Jeffrey Vacirca, and Pentagon health official Stephen Ferrara. Trader odds stay dispersed because the process is still in vetting without a confirmed frontrunner, Senate confirmation timeline, or binding deadline before year-end. Key differentiators among mentioned names such as former commissioner Stephen Hahn, Brett Giroir, Grace Graham, and Sara Brenner include prior FDA or HHS leadership, oncology or regulatory expertise, and alignment with current administration priorities on drug approvals, food safety, and industry relations. Support could consolidate behind one candidate through Senate vote counts, direct White House endorsement, or demonstrated ability to navigate confirmation hearings in an election year.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया
बाहरी लिंक से सावधान रहें।
बाहरी लिंक से सावधान रहें।
अक्सर पूछे जाने वाले प्रश्न